Supreme Court Upholds Mifepristone Access via Telehealth

On Thursday, the U.S. Supreme Court ruled to maintain the availability of the abortion pill mifepristone through telehealth services, countering a lower court's ruling that sought to ban its distribution by mail.

This decision, issued around 5:30 p.m., comes as part of a case initiated by Louisiana against the U.S. Food and Drug Administration (FDA).

The ruling preserves the status quo while the case is under review, following a May 1 decision from the New Orleans-based U.S. 5th Circuit Court of Appeals. Justices Samuel Alito and Clarence Thomas publicly dissented, with Alito criticizing the order as unreasonable and suggesting it undermines the Supreme Court's previous decision in Dobbs v.

Jackson Women's Health Organization, which overturned Roe v. Wade.

The ruling is significant as it affects access to abortion care across the nation, with telehealth processes allowing patients to connect with healthcare providers online. The FDA did not respond to the Supreme Court's request for a brief, and the case has drawn amicus briefs from various states and organizations.